Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bioendo, officially Xiamen Bioendo Technology Co., Ltd., is a leading manufacturer specializing in endotoxin and beta-glucan detection reagents and kits. Founded in 1978, the company is recognized as a pioneer in the production of Limulus Amebocyte Lysate (LAL) and Tachypleus Amebocyte Lysate (TAL) reagents in China. Bioendo provides a comprehensive range of products including gel-clot, chromogenic, and turbidimetric assays, as well as endotoxin-free consumables and specialized detection equipment. Their solutions are widely used in the pharmaceutical, medical device, and life science research industries to ensure product safety and quality control. The company also develops specialized software for kinetic readers to facilitate automated and high-throughput testing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bioendo.